Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trazodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 12/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 12/20 | 1.00 |
| ▸ | DRD2 | P14416 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trazodone SCHEMBL29390760 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL28226073 | 0.99 | HTR1A (0.98) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL29575935 | 0.99 | KDM4E (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL3402550 | 0.99 | KDM4E (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL61754 | 0.99 | KDM4E (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL120883 | 0.98 | HTR1A (0.96) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL11089944 | 0.98 | HTR1A (0.98) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL27570399 | 0.95 | DRD2 (0.90) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL8741340 | 0.94 | DRD2 (0.89) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL23145121 | 0.93 | HTR1A (0.87) | HTR1ADRD2HTR2AKCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29276 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-4709372-A1 | SMALL MOLECULE INHIBITORS OF GLUTAMINASE | Leal Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| EP-0303961-A2 | Novel antidepressants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-02-22 | — | — | EP | claimed |
| US-4698342-A | INCREASED SEROTONIN LEVEL; TRYPTOHAN PRECURSOR, TRAZODONE; REUPTAKE INHIBITOR, NARCOTIC MIX | SEROTONIN INDUSTRIES OF CHARLESTON (US) | 1987-10-06 | — | — | US | claimed |
| US-4687771-A | TRAZODONE | BRISTOL-MYERS COMPANY (US) | 1987-08-18 | — | — | US | claimed |
| EP-0222782-A4 | COMPOSITIONS FOR CONTROLLING PAIN, DEPRESSION AND SEDATION. | SEROTONIN IND (US) | 1987-08-12 | — | — | EP | claimed |
| EP-0222782-A1 | COMPOSITIONS FOR CONTROLLING PAIN, DEPRESSION AND SEDATION. | SEROTONIN IND (US) | 1987-05-27 | — | — | EP | claimed |
| WO-1986005684-A1 | METHOD AND COMPOSITIONS FOR CONTROLLING PAIN, DEPRESSION AND SEDATION | SEROTONIN INDUSTRIES OF CHARLESTON (US) | 1986-10-09 | — | — | WO | claimed |
| US-4596807-A | Administering L-tryptophan, L-5-hydroxytryptophan as serotonin precursor | SEROTONIN INDUSTRIES OF CHARLESTON (US) | 1986-06-24 | — | — | US | claimed |
| US-4162318-A | Use of trazodone and etoperidone in Parkinsonism and in other extrapyramidal syndromes characterized by tremors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1979-07-24 | — | — | US | claimed |
| US-4131675-A | Use of combinations of L-DOPA with trazodone and L-DOPA with etoperidone in Parkinsonism | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1978-12-26 | — | — | US | claimed |